TG Therapeutics signs $645M deal to kick-start international launch of MS antibody
TG Therapeutics is looking to expand access to its CD20 antibody Briumvi outside North America and has announced a partnership with the European pharma company Neuraxpharm.
The deal is for $140 million in cash upfront, plus another $12.5 million once the drug, approved in the US and EU for adults with relapsing forms of multiple sclerosis, is launched in the first EU member country, according to a press release Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.